NOD2 mutations and anti-saccharomyces cerevisiae antibodies are risk factors for crohn's disease in African Americans

American Journal of Gastroenterology

Volumn 105, Issue 2, 2010, Pages 378-386

  Dassopoulos, Themistocles ^a   Nguyen, Geoffrey C ^a,b   Talor, Monica Vladut ^a   Datta, Lisa Wu ^a   Isaacs, Kim L ^c   Lewis, James D ^d   Gold, Michael S ^e   Valentine, John F ^f   Smoot, Duane T ^g   Harris, Mary L ^a   Oliva Hemker, Maria ^a   Bayless, Theodore M ^a   Burek, C Lynne ^a   Brant, Steven R ^a,h  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e WASHINGTON HOSPITAL CENTER   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; FUNGUS ANTIBODY; INFLIXIMAB; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ANTIBODIES, FUNGAL; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; HUMANS; MALE; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; RISK FACTORS; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 76349102817     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.575     Document Type: Article

References (50)

1. Bayless T M, Tokayer A Z, Polito JM II, et al. Crohn's disease: concordance for site and clinical type in af ected family members-potential hereditary infuences. Gastroenterology 1996;111:573-579
2. Polito JM II, Childs B, Mellits E D,et al. Crohn's disease: inf uence of age at di-agnosis on site and clinical type of disease. Gastroenterology 1996;111:580-586
3. Gasche C, Scholmerich J, Brynskov J et al. A simple classif cation of Crohn's disease: Report of the Working Party for the World Congresses of Gastro-enterology, Vienna 1998. Infamm Bowel Dis 2000; 6, 8-15.
4. Silverberg M S, Satsangi J, Ahmad T et al. Toward an integrated clinical, mo-lecular and serological classif cation of inf ammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 (Suppl A): 5-36.
5. Hugot JP, Chamaillard M, Zouali H et al.AssociationofNOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
6. Ogura Y, Bonen DK, Inohara N et al. Aframeshif mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606
7. Economou M, Trikalinos T A, Loizou K T et al.Diferential efects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a meta-analysis. Am J Gastroenterol 2004;99:2393-2404
8. Brant SR, Picco MF, Achkar JP et al. Defning complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Infamm Bowel Dis 2003;9:281-289
9. Ahmad T, Armuzzi A, Bunce M et al. T e molecular classif cation of the clinical manifestations of Crohn's disease. Gastroenterology 2002;122:854-866
10. Lesage S, Zouali H, Cezard J P et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inf ammatory bowel disease. Am J Hum Genet 2002;70:845-857
11. Annese V, Lombardi G, Perri F et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease-an IG-IBD study. Am J Gastroenterol 2005;100:84-92.
12. Abreu M T, Taylor K D, Lin Y C et al. Mutations in NOD2 are associated with f brostenosing disease in patients with Crohn's disease. Gastroenterology 2002;123:679-688
13. Cuthbert AP, Fisher SA, Mirza MM et al. The contribution of NOD2 gene mutations to the risk and site of disease in inf ammatory bowel disease. Gastroenterology 2002;122:867-874
14. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002;359:1661-1665
15. Vermeire S, Wild G, Kocher K et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002;71:74-83.
16. Radlmayr M, Torok H P, Martin Ketal. The c-insertion mutation of the NOD2 gene is associated with f stulizing and f brostenotic phenotypes in Crohn's disease. Gastroenterology 2002; 122: 2091-2092
17. Helio T, Halme L, Lappalainen M et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 2003;52:558-562
18. Dassopoulos T, Frangakis C, Cruz-Correa M et al. Antibodies to Sac-charomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Infamm Bowel Dis 2007;13:143-151
19. Peeters M, Joossens S, Vermeire S et al. Diagnostic value of anti-Saccharo-myces cerevisiae and antineutrophil cytoplasmic autoantibodies in inf am-matory bowel disease. Am J Gastroenterol 2001;96:730-734
20. Quinton JF, Sendid B, Reumaux D et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoanti-bodies in inf ammator y bowel disease: prevalence and diagnostic role. Gut 1998;42:788-791
21. Vasiliauskas E A, Kam L Y, Karp L C et al. Marker antibody expression strati-f es Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-96.
22. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Infamm Bowel Dis 2001;7:8-15.
23. Sostegni R, Daperno M, Ercole E et al. Detection of anti-Saccharomyces cerevisiae antibodies in Crohn's disease: is it a reliable diagnostic and prognostic marker? Dig Liver Dis 2001;33:755-761
24. Mow W S, Vasiliauskas E A, Lin Y C et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004;126:414-424
25. Smith B R, Arnott ID, Drummond H E et al. Disease location, anti-Saccharomy-ces cerevisiae antibody, and NOD2/CARD15 genotype inf uence the progression of disease behavior in Crohn's disease. Inf amm Bowel Dis 2004; 10: 521-528
26. Walker L J, Aldhous M C, Drummond H E et al.Anti-Saccharomyces cerevi-siae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 2004;135:490-496
27. Riis L, Vind I, Vermeire Setal. T e prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Infamm Bowel Dis 2007;13:24-32.
28. Forcione D G, Rosen M J, Kisiel J B et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004;53:1117-1122
29. Papp M, Altorjay I, Norman G L et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninf ammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Infamm Bowel Dis 2007;13:984-92.
30. Kugathasan S, Loizides A, Babusukumar U et al. Comparative phenotypic and CARD15 mutational analysis among African American, Hispanic, and white children with Crohn's disease. Infamm Bowel Dis 2005;11:631-638
31. Nguyen GC, Torres EA, Regueiro M et al. In fammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic whites: characterization of a large North American cohort. Am J Gastroen-terol 2006;101:1012-1023
32. Basu D, Lopez I, Kulkarni A et al. Impact of race and ethnicity on inf am-matory bowel disease. Am J Gastroenterol 2005; 100: 2254-2261
33. Ogunbi S O, Ransom J A, Sullivan K et al. In fammatory bowel disease in African-American children living in Georgia. J Pediatr 1998; 133: 103-107
34. Eidelwein AP, Tompson R, Fiorino K et al. Disease presentation and clinical course in black and white children with inf ammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 555-560
35. Cross R K, Jung C, Wasan S et al. Racial dif erences in disease phenotypes in patients with Crohn's disease. Infamm Bowel Dis 2006;12:192-198
36. Wang M, Kugathasan S, Cho J et al. African and European genetic admixture in African American IBD patients. Infamm Bowel Dis 2008;14:S8.
37. Dassopoulos T, Nguyen GC, Bitton A et al. Assessment of reliability and validity of IBD phenotyping within the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium (IBDGC). Infamm Bowel Dis 2007;13:975-983
38. Satsangi J, Silverberg M S, Vermeire S et al. The Montreal classif cation of inf ammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-753
39. Brant SR, Wang M H, Rawsthorne P et al. A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. Am J Gastroenterol 2007;102:313-323
40. Vermeire S, Joossens S, Peeters M et al. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in infammatory bowel disease. Gastroenterology 2001;120:827-833
41. Schlesselman JJ. Case-Control Studies: Design, Conduct, Analysis (Monographs in Epidemiology and Biostatistics). Oxford University Press: New York, USA, 1982.
42. Croucher P J, Mascheretti S, Hampe J, et al. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet 2003;11:6-16.
43. Gao M, Cao Q, Luo LH et al. NOD2/CARD15 gene polymorphisms and susceptibility to Crohn's disease in Chinese Han population]. Zhonghua Nei Ke Za Zhi 2005;44:210-212
44. Zaahl M G, Winter T, Warnich L et al. Analysis of the three common mutations in the CARD15 gene (R702W, G908R and 1007fs) in South African colored patients with inf ammatory bowel disease. Mol Cell Probes 2005;19:278-281
45. Hugot JP, Zaccaria I, Cavanaugh J, et al. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol 2007; 102: 1259-1267
46. Gasche C, Nemeth M, Grundtner P et al. Evolution of Crohn's disease-associated Nod2 mutations. Immunogenetics 2008;60:115-120
47. Meinzer U, Esmiol-Welterlin S, Barreau F et al. Nod2 mediates susceptibility to Yersinia pseudotuberculosis in mice. PLoS ONE 2008;3:e2769.
48. Klebl F H, Bataille F, Hofstadter F et al. Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease. Int J Colorectal Dis 2004; 19: 319-324
49. Lawrance I C, Murray K, Hall A et al. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastro-enterol 2004;99:2186-2194
50. Kurata JH, Kantor-Fish S, Frankl H et al. Crohn's disease among ethnic groups in a large health maintenance organization. Gastroenterology 1992;102:1940-1948